Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline and Aeras ally on tuberculosis vaccine

GlaxoSmithKline and Aeras ally on tuberculosis vaccine

16th October 2012

GlaxoSmithKline has signed an agreement with tuberculosis (TB) vaccine development organisation Aeras to advance an investigational treatment for the deadly disease.

The companies will be sharing resources, capabilities and knowhow to progress the development of a new TB vaccine containing GlaxoSmithKline's proprietary M72 antigen and AS01E adjuvant.

Early-stage trials have shown the promise of this compound in terms of its immune response and safety and reactogenicity profile, with a follow-up phase IIb trial planned for next year in Kenya, India and South Africa.

The need for a new TB vaccine is great, as the current standard BCG therapy is unable to effectively prevent pulmonary forms of TB on its own.

Jim Connolly, president and chief executive officer of Aeras, said the alliance will be essential in "getting us that much closer to potentially one day having a TB vaccine that could protect adolescents and adults from one of the world's deadliest infectious diseases".

Last week, GlaxoSmithKline outlined its commitment to advancing openness and collaboration in order to tackle global health issues at a London meeting hosted by the Wellcome Trust.ADNFCR-8000103-ID-801469936-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.